Should glargine (insulin glargine) be held if blood glucose (BG) is less than 100 mg/dL?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Glargine Insulin with Blood Glucose Less Than 100 mg/dL

Glargine insulin should be held if blood glucose is less than 100 mg/dL to prevent hypoglycemia, as administering insulin when blood glucose is already low significantly increases the risk of developing more severe hypoglycemia. 1

Rationale for Holding Glargine When BG < 100 mg/dL

  • The American Diabetes Association defines hypoglycemia as any blood glucose level <70 mg/dL (3.9 mmol/L), which represents the initial threshold for counterregulatory hormone release 1
  • For hospitalized patients specifically, insulin regimens should be reassessed if blood glucose falls below 100 mg/dL (5.6 mmol/L) to prevent hypoglycemia 1
  • Fasting glucose levels <100 mg/dL are predictors of hypoglycemia within the next 24 hours 2
  • Severe hypoglycemia can lead to significant morbidity including cognitive impairment, seizures, coma, and in rare cases, mortality 1

Hypoglycemia Risk with Glargine Insulin

  • Although insulin glargine provides a relatively constant basal level of circulating insulin with no pronounced peak compared to NPH insulin, it still carries a risk of hypoglycemia 3
  • Studies show that insulin glargine has a reduced risk of hypoglycemia compared to NPH insulin, but the risk is not eliminated, especially when blood glucose levels are already low 4
  • In clinical trials, severe hypoglycemia and severe nocturnal hypoglycemia were reduced with insulin glargine by 46% and 59% respectively compared to NPH insulin, but still occurred 4

Algorithm for Managing Glargine Insulin When BG < 100 mg/dL

  1. Hold the dose: If blood glucose is <100 mg/dL, hold the glargine insulin dose 1
  2. Treat hypoglycemia if present: If blood glucose is <70 mg/dL, treat hypoglycemia first before considering any insulin administration 1
  3. Reassess insulin regimen: Review the overall insulin regimen and consider dose reduction for subsequent doses 2
  4. Adjust basal insulin dose: If fasting blood glucose is consistently <100 mg/dL or if >2 fasting values per week are <80 mg/dL, decrease the glargine dose by 2 units 2
  5. Monitor closely: Increase frequency of blood glucose monitoring to ensure recovery and stability 2

Special Considerations

  • Patients with a history of hypoglycemia unawareness may require higher glucose thresholds (>100 mg/dL) before insulin administration 1
  • Elderly patients and those with renal or hepatic impairment are at higher risk of hypoglycemia and may benefit from more conservative thresholds 1
  • For hospitalized patients, a target glucose range of 140–180 mg/dL (7.8–10.0 mmol/L) is recommended for most critically ill and noncritically ill patients, making a threshold of 100 mg/dL appropriate for holding insulin 2

Clinical Pitfalls to Avoid

  • Never administer insulin when blood glucose is already in the hypoglycemic range (<70 mg/dL or 3.9 mmol/L) 1
  • Avoid relying solely on symptoms to determine if a patient is hypoglycemic; always confirm with blood glucose measurement 1
  • Do not discontinue basal insulin completely based on a single low reading; instead, adjust the dose appropriately for subsequent administrations 2
  • When simplifying insulin regimens, particularly in older adults, fasting glucose goals of 90–150 mg/dL (5.0–8.3 mmol/L) are appropriate, supporting the practice of holding insulin when glucose is <100 mg/dL 2

References

Guideline

Blood Glucose Threshold for Insulin Administration

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Insulin glargine (Lantus).

International journal of clinical practice, 2002

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.